About 64 million Americans have high levels of sebaceous protein (A), or LP (A), a type of cholesterol that can increase the risk of heart attack and other cardiovascular problems.
The presence of the high LP (A) does not appear in routine tests because lifestyle factors such as diet and exercises do not seem to affect it and there have been no medications to treat them – yet.
LePodisiran – an experimental drug by drug Eli Lilly – was found to reduce this fatal cholesterol by approximately 94 % after one dose.
Participants who received JAB again on a six -month sign showed approximately 95 % decrease in LP (A) levels after one year.
The results were presented on Sunday at the annual meeting of the American College of Heart Diseases in Chicago and published in the New England Medicine Journal.
“This is a major source of cardiovascular disease,” said the lead author, Dr. Stephen Nissen, the chief academic official at the Heart Institute and the Vascular and Sadr Institute at the Cleveland Clinic.
“We have never been able to treat sebaceous protein (A) yet.”
The sebaceous protein (A), or LP (A), is a body produced from the liver-like LDL- “bad cholesterol”-which contributes to the accumulation of plaque in the arteries, which greatly increases the risk of heart attacks and strokes.
Unlike other types of cholesterol, LP (A) levels are mainly dictated by your genes, making lifestyle changes ineffective in managing their concentration.
Nissen said: “Nearly a quarter of the world's population has high levels of LP (A), which exposes them to a much greater risk of cardiovascular events such as heart attacks and strokes,” Nissen said.
Unfortunately, there are no approved treatments to reduce cholesterol in particular for the genetic risk factor, lifestyle changes such as diet and exercises do not provide meaningful discounts.
“These important and sustainable discounts (A) are encouraging and indicate that our path methods such as Lepodisiran can provide strong benefits with long -term doses.”
While the results are encouraging, experts warn that more research is necessary to confirm the safety and effectiveness of the drug for the public.
“Reducing the risk of cardiovascular inherited for patients with high LP (A) has not extended for a long time. These results provide hope for a long -term and durable treatment option.”
“This data emphasizes Lily's commitment to the progress of genetic medicine to address one of the world's most health care challenges. We will continue to assess the potential benefits of Blempicrin in experimenting with continuous cardiovascular results.”
